CliffBio
small molecule

AMTURNIDE

ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE

Loss of exclusivity—loss of exclusivity
CompanyNovartis →See this company's full patent-cliff portfolio

Drug detail

Brand nameAMTURNIDE
Active ingredientALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE
StrengthEQ 300MG BASE;EQ 5MG BASE;12.5MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalDecember 2010
Marketing statusDISCN

More from Novartis

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.